Abstract The use of lanthanide-based contrast agents for magnetic resonance imaging has become an integral component of this important diagnostic modality. These inert chelates typically possess high thermodynamic stability constants that serve as a predictor for in vivo stability and low toxicity. Recently, a new class of contrast agents was reported having a significantly lower degree of thermodynamic stability while exhibiting biodistribution profiles indicative of high stability under biological conditions. These observations are suggestive that the nature of contrast agent stability is also dependent upon the kinetics of complex dissociation, a feature of potential importance when contemplating the design of new chelates for in vivo use. We present a study of the kinetics of acid-catalyzed dissociation, thermodynamic stability, serum stability, and biodistribution of a series of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-tetraamide complexes that have been substituted with peripheral hydroxyl groups. The data indicate that these nontraditional contrast agents exhibit in vivo stability comparable to that of agents with much higher log K ML values, demonstrating the important contribution of kinetic inertness.
Introduction
Magnetic resonance imaging (MRI) has become one of the most powerful noninvasive tools for modern diagnostic medicine. To a large extent, growth and acceptance of this modality have been strongly influenced by the use of paramagnetic contrast agents which enhance image quality and soft tissue delineation, thus providing additional information for a more rapid and accurate diagnosis [1, 2] . For this purpose gadolinium chelates have proven to be the most versatile family of contrast agents owing to their high spin state and long electronic relaxation times which reduce the relaxation rate of water protons in tissue, resulting in enhanced image contrast. The primary mechanism of relaxation by gadolinium-based magnetopharmaceutical agents is dependent upon the rapid exchange of metalcoordinated water molecules with surrounding bulk water which then generates a higher-contrast image owing to the shorter relaxation times of the bulk water.
Equally important to MRI contrast agent development has been the refinement of ligand structures needed to effectively render the lanthanide ion nontoxic. A variety of both acyclic and cyclic ligand frameworks are frequently employed for imaging modalities, each having unique properties that can be adapted to meet the requirements of a specific application (Fig. 1) . Despite certain structural variations, these ligand systems all possess the common features necessary for generating stable complexes for in vivo use; i.e., the familiar octadentate coordination geometry and neutral or anionic charge imparted by the polyaminocarboxylate ligand framework. This signature coordination geometry is present in both the linear and the macrocyclic structures best exemplified by the workhorse ligands diethylene triamine pentaacetic acid (DTPA) and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). Over the years these two ligands have served as the foundation for nearly all medical applications of lanthanide ions, a consequence of their unsurpassed chelation properties. Ultimately these collective traits afford proven drug formulations that are nontoxic at the necessary doses and exhibit very efficient renal clearance profiles for all current MRI contrast agents.
An exciting new development in the field of contrast agents has been the discovery that certain types of paramagnetic chelates with moderate water exchange rates can be used to generate contrast enhancement by an entirely different mechanism [3] . Unlike their predecessors, these new contrast agents make possible the selective presaturation of the bound water molecule owing to slower water exchange kinetics. Once saturated, the bound water molecule exchanges (it is no longer coordinated to the metal), becoming part of the surrounding water pool where it -based magnetic resonance imaging contrast agents transfers the saturation effect to neighboring water protons. The net result is that diminished image intensity is observed in regions that contain contrast agent. Large lanthanideinduced chemical shifts of the bound water protons alleviate the problems of direct saturation of the solvent water while permitting more rapid saturation transfer. The process of altering proton signal intensity via selective presaturation of a neighboring pool of protons is commonly referred to as ''chemical exchange saturation transfer'' (CEST) and when CEST is produced by a paramagnetic chelate the effect is referred to as ''PARACEST.' ' The general structure of PARACEST contrast agents is strikingly similar to that of the conventional MRI agent GdDOTA and its analogues GdHPDO3A and GdDO3A-butrol (Fig. 1) . Two major structural differences exist between these PARACEST agents and their conventional counterparts. First, the central gadolinium ion is replaced by a paramagnetic lanthanide ion with an anisotropic f-electron shell that can induce significant hyperfine shifts in neighboring protons. Europium(III) is a common choice for PARACEST applications. Second, the carboxylate pendant arms of the ligand are replaced by amide ligands and this modulates the water exchange rate such that it is amenable for CEST applications. In addition, the amide substituent may be modified in such a way that further finetuning of water exchange kinetics is possible [4] . These changes in the nature of coordinate bonding with the metal ion have been found to exert an important influence over the kinetics of dissociation [5] , thermodynamic stability [5] [6] [7] , and physiological tolerance [8] . Our interest in CEST imaging using PARACEST agents has prompted an effort to refine this class of chelates with a view to in vivo applications. Of particular interest has been the effect that the nature of the amide substituent plays in controlling the magnitude of CEST and the physiological tolerance of these chelates. Stimulated by the idea that both the CEST properties and the in vivo tolerance may be improved by incorporating a large number of hydroxyl groups into the complex, we prepared and studied a series of derivatized chelates containing four [(2-hydroxyethyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetamide (L 4 )], eight [2-propyl-1,3-bishydroxy)-1,4,7,10-tetraazacyclododecane-1, 4,7,10-tetraacetamide (L 8 )], and twelve [(1,1-bishydroxymethyl-2-hydroxyethane)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetamide (L 12 )] hydroxyl groups (Fig. 2) . The CEST properties of EuL 4 , EuL 8 , and EuL 12 will be reported elsewhere (M. Woods, A. Pasha, G.E. Kiefer, D.E. Woessner, and A.D. Sherry, unpublished data). Each complex was found to exhibit a PARACEST effect arising from the coordinated water molecule but no CEST, or CEST enhancement, was observed arising from the peripheral hydroxyl groups. In this paper we examine the in vitro stability as well as the biodistribution profiles of this new class of PARACEST agents.
Materials and methods

General remarks
All chemicals were obtained from commercial sources and used without further purification unless otherwise stated. All solvents were of high performance liquid chromatography grade and used as received unless otherwise stated. Water refers to deionized water with a specific resistance of 18 MX cm -1 . The 1 H and 13 C NMR spectra were recorded using a JEOL Eclipse 270 MHz spectrometer operating at 270 MHz. Chemical shifts are reported in parts per million (d) and referenced to tetramethylsilane. IR spectra were recorded with a Nicolet Avatar 360 Fourier transform IR spectrometer using KBr pellets; UV-vis absorption spectra and kinetics were recorded using a Cary 300 Bio UV-vis spectrophotometer. Electrospray ionization (ESI) mass spectrometry (ESI) was performed by HT Laboratories, San Diego, California. Elemental analyses were performed by the Micro Laboratory, University of Illinois at Urbana Champaign. Radioisotope thin layer chromatography (TLC) analysis was performed with a Rita Star radioisotope TLC analyzer (Straubenhardt, Germany). 
tert-Butyl-2-(benzyloxy)ethyl carbamate
A solution of N-tert-butyloxycarbonylethanolamine (2; 20.0 g, 124.0 mmol) and benzyl bromide (22.1 mL, 186.0 mmol) in anhydrous dichloromethane (200 mL) was stirred at 0°C under argon. Portions of finely ground potassium hydroxide (10.4 g, 186.0 mmol) were added over a period of 30 min. After addition was complete, the mixture was stirred at room temperature for 18 h. The solvents were then removed under reduced pressure and the residue was taken up into dichloromethane (200 mL) and water (200 mL). The two layers were separated and the aqueous layer was extracted with dichloromethane (3 9 20 mL). The combined organic layers were dried (Na 2 SO 4 ) and the solvents removed under reduced pressure. The oily residue was purified by column chromatography over silica gel with elution by hexane followed by 5% EtOAc in hexane to afford tert-butyl-2-(benzyloxy)ethyl carbamate (5) N-tert-Butyl-(1,3-bisbenzyloxy)-2-propylcarbamate N-tert-Butyl-(1,3-bisbenzyloxy)-2-propylcarbamate (6) was prepared according to the procedure used for compound 5 using N-tert-butyl-(3-benzyloxy)-2-amino-1-propanol (3; 20.0 g, 75.0 mmol), benzyl bromide (13.4 mL, 113.0 mmol), and potassium hydroxide (6.4 g, 113.0 mmol). It was obtained as a colorless waxy solid (22.9 g, 86%). N-tert-Butyloxycarbonyltris(benzyloxymethyl) aminomethane N-tert-Butyloxycarbonyltris(benzyloxymethyl)aminomethane (7) was prepared according to the procedure used for compound 5 using 4 (20 g, 90 mmol), benzyl bromide (70 mL, 589 mmol), and potassium hydroxide (81. 4 
2-Benzyloxyethylamine
Trifluoroacetic acid (60 mL) was added dropwise to a solution of the carbamate 5 (18 g, 72 mmol) in CH 2 Cl 2 (150 mL) at 0°C over a period of 1 h. The reaction mixture was then stirred at room temperature for 18 h. The solvents were removed under reduced pressure and the residue was divided between EtOAc (150 mL) and 5% aqueous Na 2 CO 3 solution (150 mL). The organic layer was washed with brine, dried (Na 2 SO 4 ), and the solvents were removed under vacuum. The residue was purified by column chromatography over silica gel with elution by chloroform to afford 2-benzyloxyethylamine (8) as a pale-yellow oil (10.3 g, 95% 
2-Benzyloxyethyl-2-bromoacetamide
Potassium carbonate (11.6 g, 84 mmol) was added to a solution of the amine 8 (9.0 g, 60 mmol) in dichloromethane (250 mL) and the suspension was cooled to 0°C in an ice bath. Bromoacetyl bromide (17.0 g, 84 mmol) was added dropwise to the vigorously stirred reaction mixture over a period of 1 h. The reaction mixture was then allowed to warm to room temperature and was stirred for a further 18 h. Water (100 mL) was then added and the two layers were separated. The organic layer was dried (Na 2 SO 4 ) and the solvents were removed under reduced pressure. The residue was then purified by column chromatography over silica gel with elution by chloroform to afford 2-benzyloxyethyl-2-bromoacetamide (11) as a paleyellow oil (14.6, 90% 
Bromoacetamido N-tris(benzyloxymethyl)methane
Bromoacetamido N-tris(benzyloxymethyl)methane (13) was prepared according to the procedure used for compound 11 using the amine 10 (15.0 g, 38.0 mmol), potassium carbonate (7.5 g, 54.0 mmol), and bromoacetyl bromide (10.8 g, 54.0 mmol). It was obtained by column chromatography over silica gel with elution by 5% ethyl acetate in chloroform as a pale-yellow oil (16.7 g, 85%) . (2-Benzyloxyethyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetamide
The bromoacetamide 11 (7.89 g, 29.0 mmol) and 1,4,7,10-tetraazacyclododecane (cyclen; 1.0 g, 58 mmol) were dissolved in anhydrous acetonitrile (200 mL) and potassium carbonate (9.62 g, 70.0 mmol) was added. The resulting suspension was heated under reflux, with stirring, for 6 days. After the reaction mixture had been cooled to room temperature, the solvents were removed under reduced pressure and the residue was taken up into H 2 O (100 mL) and CH 2 Cl 2 (100 mL). The organic layer was separated and the aqueous layer extracted with CH 2 Cl 2 (3 9 15 mL). The combined extracts were dried (Na 2 SO 4 ) and the solvents were removed under reduced pressure. The residue was purified by column chromatography over silica gel with elution by 5% MeOH in CH 2 Cl 2 to afford (2-benzyloxyethyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetamide (14) (1,1-Bisbenzyloxymethyl-2-hydroxyethane)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetamide The bromoacetamide 13 (14.9 g, 29.0 mmol) and cyclen (1.0 g, 5.8 mmol) were dissolved in anhydrous acetonitrile (250 mL) and anhydrous diisopropylethylamine (20.0 mL, 115.0 mmol) was added. The resulting reaction mixture was heated under reflux, with stirring under an argon atmosphere, for 6 days. The solvents were removed under reduced pressure and the residue was taken up in water (100 mL) and CH 2 Cl 2 (100 mL). The organic layer was separated and the aqueous layer was extracted with CH 2 Cl 2 (3 9 15 mL). The combined organics were dried (Na 2 SO 4 ) and the solvents were removed under reduced pressure. The residue was purified by column chromatography over silica gel with elution by CH 2 Cl 2 followed by 5% MeOH in CH 2 Cl 2 to afford (1,1-bisbenzyloxymethyl-2-hydroxyethane)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetamide (16) as a pale-yellow semisolid (4.62 g, 42%). The tetraether 14 (3.24 g, 35 mmol) was dissolved in anhydrous MeOH (35 mL) and glacial acetic acid (10 mL).
After the solution had been degassed with argon, dried Pearlman catalyst (Pd(OH) 2 /C, 2.5 g) was added. The reaction mixture was placed on a Parr hydrogenation apparatus and was shaken under a hydrogen pressure of 65 psi for 2 days. To the slurry was added water (10 mL) and the mixture was stirred for 5 min. The catalyst was then removed by filtration and the solvents were removed under reduced pressure. The residue was taken up in water (20 mL) and loaded onto a column of Amberlite IRA 400 ion-exchange resin (OH-form). The contents of the column were eluted by distilled water and lypholization afforded (2-hydroxyethyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetamide (L 4 ) as a pale-yellow solid (1.7 g, 85% 8 , and L 12 were prepared as their trifluoromethanesulfonate (triflate) salts by mixing equimolar quantities of the appropriate lanthanide triflate and ligand in a 1:1 acetonitrile/methanol solution and heating at 50°C for 3 days. The solvents were then removed under reduced pressure and the residue was taken up into water and freeze-dried to afford the complex, which was used without further purification.
Chloride salts of L 4 , L 8 , and L 12 lanthanide complexes were prepared from an appropriate standardized lanthanide chloride solution and an equimolar quantity of ligand in aqueous solution. The solution pH was adjusted to 5.5 using 1 M NaOH and 1 M HCl as necessary and the reaction mixture was stirred at room temperature. The reaction pH was maintained in the range 5.0-5.5 by addition of 1 M NaOH solution. Reaction progress was monitored with xylenol orange indicator (0.15 M AcOH/ AcONa buffer, pH 5.5). When the indicator indicated that no free lanthanide remained, the pH was raised to 7 (1 M NaOH) and the solution was filtered and freeze-dried to afford the complex, which was used without further purification.
Potentiometric measurements
The pH-potentiometric titrations were carried out with a Thermo Orion expandable ion analyzer EA940 pH meter using a Thermo Orion 8103BN semimicro combination electrode in vessels thermostated at 25.0°C. A Metrohm DOSIMATE 665 autoburette with a 5-mL capacity was used for base additions. KCl (1.0 M) was used to maintain the ionic strength. All equilibrium measurements (direct titrations) were carried out in 10.00-mL sample volumes with magnetic stirring. During the titrations argon gas was passed over the top of the samples to ensure CO 2 -free conditions in the potentiometric cell. Electrode calibration was performed using standard buffers purchased from VWR (pH 4.005 and 9.180). The titrant, carbonate-free KOH solution, was standardized with 0.05 M potassium hydrogen phthalate solution by pH-potentiometric titration. A standard solution of HCl was prepared by dilution of concentrated HCl with doubly distilled water and its concentration was determined by pH-potentiometric titration with the standardized KOH solution. The H ? concentration was determined using a published method [9] . The pK w of water was calculated from these titration data and was found to be 13.721. The values of the protonation constants (log K i H ) and the stability constants were determined by using the PSEQUAD computer program [10] . 
To determine the thermodynamic stability constants of divalent metal ions, titrations were carried out using 1:1 and 1:2 ligand to metal ratios with the concentration of the ligand maintained at about 2.0 mM. The combined titration data were fitted simultaneously and the thermodynamic stability constants (K ML ) were evaluated and reported based on Eq. 2:
Because the complexes of lanthanide ions with DOTAtetraamide ligands form very slowly, the thermodynamic stability constants of L 4 , L 8 , and L 12 with lanthanide ions were determined using ''out-of-cell'' experiments [5, 10] . Typically, 25.0 mL of an equimolar solution of LnCl 3 and ligand, concentration approximately 2.0 mM, was prepared and divided into 16 individual solutions (1.5 mL each). The pH of each sample was then adjusted to a different pH using HCl or KOH solution such that the samples covered the pH range 2.5-5.0. The samples were properly sealed and placed in a 40°C incubator for 35 days followed by an additional 35 days at room temperature to reequilibrate the mixture to room temperature. The pH of each individual sample was then measured. The proton concentration was calculated from the measured pH values using a correction term determined according to Irving et al. [9] by titration of 14 mM strong acid (HCl) with 0.1713 M KOH as a difference between the measured and calculated pH values. Such titration was performed before and after the pH measurement in the batch samples and the average of these two measurements was used as a correction term.
Kinetic measurements
The formation rates of CeL 4 and CeL 8 were measured by spectrophotometry using a Cary 300 Bio UV-vis spectrophotometer equipped with a thermostated cell holder and semimicro quartz cells (Starna, optical path length 1.0 cm). Solutions containing 1.0 mM ligand and a 10-50-fold excess of CeCl 3 were studied and complex formation was monitored at 324 nm and 25°C. The ionic strength was maintained at 1.0 M with KCl and the pH was controlled with 0.05 M noncoordinating buffers: N-methylpiperazine (log K 1 H = 4.83) and piperazine (log K 1 H = 6.04 at I = 1.0 M and 25°C) [11] . The absorbance data were recorded as a function of time and were fitted to Eq. 3 to evaluate the first-order rate constants, where A 0 , A t , and A e are the absorbance values measured at time zero, time t and at equilibrium, respectively:
All the dissociation kinetics measurements were performed in 2.0 mM solutions of CeL complex in 0. 177 Lu to a ligand solution with the molar ratio of ligand to Lu(III) maintained at 1.2:1. The radiochemical yields and purity were determined by radio-TLC analysis.
Determination of partition coefficients
The partition coefficients (log P) of the 177 Lu-labeled complexes were determined by adding 10 lL of each 177 Lu-labeled complex to a biphasic solution containing 500 lL of n-octanol (water-saturated) and 500 lL of Mini-Q water (n = 5). The resulting solutions were then shaken for 3 h at room temperature. From each of the five samples an aliquot of 100 lL was removed from each phase and counted separately. The partition coefficient was calculated as an average logarithm value (log P) of the ratio of the counts in the octanol fraction to the counts in the water fraction from the five samples.
Serum stability
The in vitro stability in serum was evaluated by incubating 10 lL of each 177 Lu-labeled complex with 100 lL of rat serum at 37°C. At specific time points, an aliquot of the solution was taken out and analyzed by radio-TLC.
Pharmacokinetic and biodistribution studies
All animal studies were performed in compliance with guidelines set by the University of Texas Southwestern Institutional Animal Care and Use Committee. The injection doses were prepared by diluting each 177 Lu-labeled complex with 10 mM phosphate-buffered saline. Normal 4-5-week-old male healthy BALB/c mice (Harlan, IN, USA) were anesthetized with isoflurane and then 100 lL of each 177 Lu-labeled complex (approximately 5 lCi per mouse) was injected via the tail vein. The animals were anesthetized again prior to being killed at 0.5, 1, 4, 24, and 48 h after injection (n = 4 at each time point). Organs of interest (blood, heart, lung, liver, spleen, kidney, fat, muscle, intestine, stomach, and bone) were removed, weighed, and counted. Standards were prepared and counted along with the samples to calculate the percent injected dose per gram of tissue and the percent injected dose per organ. The animals of the last time point groups were housed in metabolic cages (four mice per cage) to collect urine and feces at 1, 4, 24, and 48 h after injection. For the evaluation of pharmacokinetic parameters, 5-10 lL of blood was collected from the retroorbital sinus of the animals at 2, 5, 10, 15, 30, 60, and 240 min.
The biodistribution of carrier-added complexes was performed in the same way as above. The injection doses were prepared by reconstituting each [
177 Lu]Lu complex with 10 mM phosphate-buffered saline to make a final volume of 100 lL for each dose containing 2 lmol of the complex. In light of the acute toxicity that could be caused by the high injected dose, all animals that received the carrier-added complexes were closely watched regarding their appearance, behavior, and weight loss after the intravenous injection. The animals into which [
177 Lu]Lu complexes of L 1 , L 4 , and L 8 had been injected immediately panicked, struggled, and died within 5 min of injection (n = 4). The acute toxicity experiments were repeated for the three complexes and the results were the same. No apparent toxic effects were observed on the animals that received [
177 Lu]LuL 12 , and which were sacrificed at 4, 24, and 48 h after injection (n = 4 at each time point) for the biodistribution studies as detailed above. The unpaired t test on the biodistribution data was performed using Prism, version 4.00 (GraphPad, San Diego, CA, USA).
Results and discussion
Ligand synthesis
For this study, cyclen serves as the central building block for L 4 , L 8 , and L 12 (Fig. 2) . The pendant ligating amides were prepared via selective protection (-OH ? -OR) methods to generate the appropriate a-bromo electrophiles for subsequent N-alkylation of cyclen with regeneration of the polyol functionality in the final step. A common synthetic strategy was adopted for the synthesis of L 4 , L 8 , and L 12 ligands. A tert-butyloxycarbonyl (Boc) protected amino alcohol was chosen as the starting point in each synthesis. In the case of L 4 and L 8 , suitable Bocprotected starting materials were commercially available (Scheme 1), while in the case of L 12 , the amine had to be Boc protected by reaction with di-tert-butyl carbonate. The hydroxyl groups could then be protected as benzyl ethers using benzyl bromide and potassium hydroxide as a base. In the case of the synthesis of ether 3, only one benzyl group had to be introduced because one hydroxyl group was already protected.
Deprotection of the amino groups was performed using trifluoroacetic acid followed by base extraction to afford the free base. The bromoacetamides 11, 12, and 13 were synthesized by reaction of the free amines 8, 9, and 10 with bromoacetyl bromide, with potassium carbonate as a base. These bromoacetamides were then used to alkylate cyclen using 5 equiv of alkylating agent, potassium carbonate as a base (Hünig's base was used in the case of L 12 ), and acetonitrile as a solvent. The protected ligands 14, 15, and 16 were obtained following column chromatography over silica gel. The use of Hünig's base in the case of 16 promoted better yields and avoided the sometimes problematic potassium complex formation with the ligand. Deprotection of the hydroxyl groups was found to be problematic because the benzyl ethers proved resistant to standard procedures (H 2 and 10% Pd on C). After numerous procedures had been attempted, benzyl deprotection was finally accomplished by means of hydrogenolysis in the presence of dry Pearlman catalyst in 22% v/v acetic acid in methanol. Exhaustive deprotection of the ethers 14, 15, and 16 afforded the target ligands L 4 , L 8 , and L 12 in 85, 88, and 55% overall yield, respectively. The europium and cerium complexes of ligands L 4 , L 8 , and L 12 were prepared using the appropriate lanthanide triflate in an acetonitrile/methanol mixture or from the chloride salts in water.
Complex kinetics and stability
Two factors describe the stability of a complex, its thermodynamic stability, defined by Eq. 2, and its kinetic inertness-its resistance to dissociation. The thermodynamic stability constant (log K ML ) of a complex can be determined by pH-potentiometry. The protonation constants (log K i H ) of ligands L 4 and L 8 were determined by potentiometric titration in a 1.0 M KCl ionic background. Although the K ? ion is known to form weak complexes with DOTA-tetraamide ligands, this choice of ionic background allows our data to be compared with those reported previously for similar systems [5] [6] [7] . Both L 4 and L 8 were found to have two protonation constants (Table 1 ) and by comparison with related systems these can be assigned to the protonation of opposing nitrogen atoms of the macrocyclic ring [5] [6] [7] . In each case the absolute value of the first protonation constant is slightly lower, by about half a log unit, than those observed for other tetraamides. In contrast, the absolute value of the second protonation constant is in the range of, or slightly higher than, those of other tetraamides. Thus, the total basicity, or the sum of the protonation constants, of these ligands is approximately the same as that observed for other simple DOTA-tetraamide derivatives, suggesting that L 4 is about 0.5-0.6 log units higher than for simple DOTAtetraamide complexes, whereas log K ZnL of L 4 is about 1.3 log units higher.
Determining the stability constants of complexes with L 12 proved to be a somewhat intractable problem. Rather surprisingly, a potentiometric titration of L 12 was consistent with six protonation constants in the range 2-12. We have been unable to find literature examples of either amide or hydroxyl protons that have protonation constants in this range and yet these are the only plausible candidates to which the four unexpected protonation constants can be assigned. By performing the potentiometric titration in the presence of a metal ion that rapidly forms complexes, one can normally identify protonation constants of groups involved in complex formation. The Ca 2? ion is ideal for this purpose; its coordination chemistry is comparable to that of the Ln 3? ions although it forms complexes much more rapidly and it does not form hydroxo complexes in the required pH range (log b -11 = -12.8) [12] . Titrating L 12 in the presence of 1 and 2 equiv of CaCl 2 afforded a curve that was identical to that obtained in the absence of Ca 2? . Only when a considerable excess of CaCl 2 was employed could an inflection point due neutralization of protons liberated by complex formation be observed. A second inflection point corresponding to the neutralization of protons not displaced by formation for the complex is also observed (Fig. S1 ). This behavior may be the result of slower or weaker than usual complex formation between Ca 2? and L 12 . The closeness of the values of the protonation constants observed for L 12 coupled with uncertainty in the behavior of this system in the presence of Ca 2? means that potentiometry could not be used to establish definitive protonation constants for those groups involved in complex formation. A 1 H NMR titration performed on this system afforded no additional evidence to help clarify this problem. In the absence of reliable protonation constant data for L 12 , the thermodynamic stability constants of complexes of this ligand were not determined in this work, and an alternative technique that will afford this information is being sought. The formation of lanthanide complexes with DOTAtetraamide ligands is much too slow to be measured by direct potentiometric titration. For this reason an ''out-ofcell'' approach was used to measure these stability data [16] . The log K LnL values determined for both LnL 4 and LnL 8 complexes follow a similar trend across the lanthanide series, rising across the early lanthanides before peaking around the middle of the series and decreasing slightly at the later lanthanide ions ( Table 2 ). The increase in stability across the early lanthanides is also observed for other DOTA-tetraamide systems. However, the decrease in stability over the later lanthanides is more marked than that observed for any of the other DOTA-tetraamides in Table 2 ; indeed some of these other complexes continue to increase in stability across the late lanthanides. The stability constants of LnL 4 and LnL 8 complexes are slightly lower than those determined for most other DOTA-tetraamide systems, a reflection of the lower first protonation constants observed for these ligands.
For a lanthanide complex to be considered safe for use in vivo, it is imperative that it be excreted from the body intact prior to any metal ion release from the ligand. Thus, for in vivo applications, kinetic inertness is a more important factor in determining safety than the thermodynamic stability constant of the complex. The rates of dissociation of DOTA-tetraamide complexes are extremely slow [5] ; therefore, to measure such rates a large excess of Table 1 The protonation constants (log K i ) of selected DOTA-tetraamide ligands and the thermodynamic stability constants (log K ML ) of their complexes with endogenous divalent metal ions (M 2? [5] b From [17] c From [13] [14] [15] J Biol Inorg Chem (2009) 14:421-438 431 acid must be used to accelerate the process. The rate of acid-catalyzed dissociation for Ce 3? complexes is readily measured by monitoring the distinctly different UV absorbance bands produced by the free Ce 3? ion and its corresponding complex. Samples of CeL 4 , CeL 8 , and CeL 12 complexes were prepared in various concentrations of acid (0.5-3.0 M HCl) such that the total ionic strength (KCl plus HCl concentration) was maintained at 3.0 M in each sample. The Ce 3? absorbance at 324 nm was then measured as a function of time. Under these conditions the pseudo-first-order rate constant, characterizing the dissociation rate (k d ), arises from two dissociation mechanisms: the spontaneous dissociation of the metal ion characterized by the rate constant k 0 and the proton-assisted dissociation characterized by the rate constant k 1 . The two mechanisms are related according to Eq. 4:
Plotting the observed dissociation rates, k d , as a function of acid concentration afforded straight lines from which the values of k 0 and k 1 were determined for each complex (Table 3) . When these dissociation rate constants, k 0 and k 1 , are compared with the log K ML values determined for DOTA-tetraamide complexes (Tables 2, 3) , the two measures of stability are found to correlate closely: the higher the thermodynamic stability constant of a complex, the smaller both the spontaneous and the acid-catalyzed dissociation rate constants. However, this correlation between kinetic and thermodynamic stability no longer holds true if the ligating groups of the pendant arm are changed from amides to acetates. CeDOTA, with four acetate pendant arms, has a much higher thermodynamic stability than any of the DOTA-tetraamide complexes and this may well result in the apparent absence of spontaneous dissociation in this system. However, the rate constant for acid-catalyzed dissociation (k 1 ) is much larger than those observed for the DOTA-tetraamide complexes (except CeL 12 ) because coordinated acetates, unlike coordinated amides, can be protonated in acidic media, resulting in dissociation of the pendant arms.
As with the thermodynamic stability measurements, L 12 behaved unusually in these experiments. Fitting the data obtained for CeL 12 afforded a large negative value of k 0 with large uncertainty, suggesting that either spontaneous dissociation does not occur in the case of CeL 12 or that a different mechanism of dissociation may occur under mildly acidic conditions (H ? concentration below 0.25 M). It also must be emphasized here that the k 0 values are determined by linear extrapolation, which is known to provide good results only when it is used not too far beyond the known data range. Additionally, the dissociation of the complex may take place by an entirely different mechanism when moving from 1.0 to 2.0 M acid concentration to the acid concentration range of 0.25 M. The acidcatalyzed dissociation constant, k 1 , for CeL 12 was also found to be much larger, more than 3 times larger, than that of even CeDOTA. Clearly this is not a desirable attribute of a complex postulated for use in vivo; however, it is important to consider that acid-catalyzed dissociation is of much less concern under the mildly basic conditions that prevail in vivo. Perhaps of greater importance in vivo is the rate of spontaneous dissociation which was observed for all Table 3 Proton-assisted dissociation rates for Ce 3? complexes of DOTA and selected DOTA-tetraamides
2.6 9 10 (1,1-bishydroxymethyl-2-hydroxyethane)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetamide, ND not determined a From [5] b The large negative value may be explained by a different mechanism accessible for dissociation at lower acid concentrations c From [18] DOTA-tetraamide complexes (except L 12 ) but not for DOTA. Furthermore, other mechanisms of complex dissociation are believed to occur in vivo, including transmetallation, particularly with Zn 2? and Cu 2? , and ligand transfer reactions. Indeed, it is widely believed that transmetallation with Zn 2? is the most important mechanism contributing to the release of Ln 3? ions from their complexes in vivo.
The interplay of endogenous ligands and metal ions and their effect on metal complex dissociation in a biological milieu is complicated and nearly impossible to mimic in vitro. We therefore set out to assess the stability of these lanthanide complexes in biological media by assessing their stability in serum and evaluating their tissue distribution in normal mice. A number of lanthanide radioisotopes are available but 177 Lu (t 1/2 = 6.62 days; b -0.498 MeV, 78.6%; c 208 keV, 11%) has shown versatility in both imaging and radiotherapy applications owing to its relatively low energy c photons and
, and L 12 were successfully labeled with 177 Lu under no-carrier-added or carrier-added conditions with 177 LuCl 3 in ammonium acetate buffer (pH 6.5, 2 h) ( Table 4) . Radiochemical yields were determined by radio-TLC and conversions were found to be quantitative in each case. An aliquot (10 lL) of each 177 LuL complex was added to rat serum (100 lL) and the sample was incubated at 37°C to assess the serum stability of the 177 LuL complex. The complex concentration in these experiments was in the range 0.33-0.83 mM. Samples of the complex in rat serum were analyzed by radio-TLC after 24 h and the activity at the known R f of the complex was then compared with the total activity in all other regions of the TLC plate. It was assumed that the intact complex would exhibit the known R f of the complex and that any activity from other parts of the plate corresponded to metal that had dissociated from the ligand. Lu observed (Table 4) . This indicates that the high kinetic in vitro stability of these complexes (vide supra) transfers to the ex vivo serum environment and furthermore suggests that these complexes are indeed stable enough for use in vivo. The octanol/water partition coefficient (log P, octanol/water) data (Table 4) demonstrate that the additional peripheral hydroxyl groups on LuL 12 impart increased hydrophilicity with respect to LuL 4 and LuL 8 .
Biodistribution studies
The distribution of a chelate at different times after injection also provides some insight into complex stability in vivo. Lanthanide ions liberated from the complex are known to accumulate in teeth and bone [20, 21] but are also taken up by liver and spleen as aggregates of the lanthanide ions with native proteins as they are cleared through the hepatobiliary and reticuloendothelial systems [22] . ). The animals were killed at 0.5, 1, 4, and 24 h after injection and organs of interest were excised and weighed and the activity was counted. The biodistribution data are summarized in Table 5 (percent injected dose per gram of tissue) and Table S3 (percent injected dose per organ).
All five compounds were cleared largely by kidney filtration (more than 90%) within 1 h of administration. It has [24] . Over the course of the first hour after injection, the four positively charged complexes showed significantly (p \ 0.05) higher uptake than 177 LuL 2 in the major organs (blood, liver, spleen, kidneys, and lungs), the notable exception being muscle, for which both 177 LuL 2 and 177 LuL 12 exhibited markedly higher uptake than the other chelates in this study. Over a longer time period, however, all five complexes studied here exhibited rapid clearance from the major organs with low residual activity observed at 4 and 24 h after injection irrespective of overall charge.
Perhaps the most marked difference in tissue distribution was observed in bone uptake of the positively charged complexes. All four positively charged complexes exhibit higher levels of activity in the bone than 177 LuL 2 at 0.5 and 1 h after injection. Although the free lanthanide ions are known to accumulate in the bone, because the rates of complex dissociation are so slow it is unlikely that the elevated activity in bone seen here at the early time points is the result of dissociation of the complex. The activity in the bone decreases quite rapidly and at 24 h after injection the level of bone activity seen for all five chelates is comparable. This is in stark contrast to free lanthanide ions that gradually build up in bone, increasing activity over time [20] . Secondly, the data obtained for liver and spleen are not indicative of dissociation of the complexes [22] 12 showed the lowest levels of liver uptake at 1 h after injection. Overall these complexes exhibited low levels of liver uptake, indicating that both hepatobiliary clearance and complex dissociation do not occur to a significant extent. The percent injected dose per organ for the spleen is extremely low for all five chelates and, since dissociation of the metal ion would surely lead to elevated activity levels in the spleen, this is a good indication that for each complex little or no dissociation of the metal ion occurs prior to excretion.
The rate of blood clearance of a chelate is an important pharmacokinetic property. It has previously been reported that the biological half-life of drugs in the bloodstream can be increased by incorporating poly(ethylene glycol) groups into the drug [25] [26] [27] [28] (Table 6 ). While the distribution half-lives (t 1/2a ) of the four positively charged complexes were similar (8.7-10.6 min), the elimination half-lives (t 1/2b ) and AUC 0?? values correlated with the number of peripheral hydroxyl groups in each complex.
The MRI contrast media used in clinical practice today ( Fig. 1) are administered in high doses (0.1 mmol kg -1 ), 3 orders of magnitude greater than the doses employed in these biodistribution experiments. PARACEST agents, which are currently limited by their relative lack of sensitivity relative to Gd 3? -based agents, may require even higher doses, although future improvements in sensitivity will almost certainly reduce these dosing requirements. Such high doses can overwhelm transport pathways in the body, significantly altering the biodistribution profiles [20] . It has recently been reported that some tricationic DOTAtetraamide complexes are acutely toxic in rodents at these high dose levels [8] . To assess the effect of this increased dose, injections of all five chelates were formulated with carrier added. A solution of 177 LuCl 3 was added to cold LuCl 3 (carrier) prior to addition of the ligand, which was slightly in excess (1.2 equiv) relative to the total concentration of Lu 3? , to form a carrier-added 177 Lu-labeled complex so that when administered at 0.1 mmol kg -1 it would only provide the same level of radiation as in the previous experiment.
No toxic effects were observed for any of the chelates when low doses of no-carrier-added complexes (0.3 lmol kg -1 ) were administered. In contrast, animals administered with carrier-added complexes of LuL 1 , LuL 4 , and LuL 8 (total Lu 3? concentration 0.1 mmol kg -1 ) showed signs of distress immediately after injection and expired within 5 min. Given the slow rate of complex dissociation established both in vitro and in serum, death occurs too rapidly to be the result of dissociation of the complex and must be the result of an inherent toxicity of these tricationic complexes, consistent with our earlier report [8] . The cause of death was previously postulated to involve an interaction between the complex and heart tissue that caused a rapid weakening of the heartbeat [8] . It is well known that cells can be more efficiently penetrated by positively charged agents [30] because of positive charge facilitated internalization and this may be the root of their effect on the heart and their subsequent toxicity.
In sharp contrast, neither LuL 2 nor LuL 12 was observed to cause any appreciable toxic effects over the entire 48-h observation period. This result was anticipated for the negatively charged LuL 2 complex, which had previously been administered to rodents at typical MRI doses [8] . It was more surprising in the case of LuL 12 complex, which probably retains some level of positive charge, despite the apparent presence of relatively acidic amide or hydroxyl protons that may reduce the overall charge somewhat. To our knowledge LuL 12 is the first example of a positively charged lanthanide DOTA-tetraamide complex that is not toxic when administered at a typical MRI dose. While the precise reasons for this absence of acute toxicity at 0.1 mmol kg -1 are uncertain, one can draw an analogy between the complexes LuL 1 , LuL 4 LuL 8 , and LuL 12 and the clinically approved MRI contrast agents GdHP-DO3A and GdDO3A-butrol (Fig. 1) . GdHP-DO3A and GdDO3A-butrol are structurally analogous with the Gd 3? ion coordinated by the macrocyclic ring, three acetate pendant arms, and one ethyl hydroxyl group. The only difference between the two complexes is the substitution of the methyl substituent of the hydroxyl pendant arm of HP-DO3A for an ethanediol in DO3A-butrol. This small change, incorporating two peripheral hydroxyl groups in DO3A-butrol, has a significant effect on the LD 50 of the complexes, increasing from 12 mmol kg -1 for GdHP-DO3A to 23 mmol kg -1 for GdDO3A-butrol [31] . Since this decrease in toxicity can only be ascribed to the introduction of the peripheral hydroxyl groups, we suggest that excess hydroxyl groups in LuL 12 render this complex less toxic, even at the doses required for MRI.
Tissue distribution profiles of carrier-added LuL 12 in normal BALB/c mice were determined at 4, 24, and 48 h after injection. For comparative purposes, the biodistribution profiles without carrier added and with carrier added are presented together in Table 7 . In general, when the complex is administered at the higher dose, a greater uptake by the major organs is observed. The complex is primarily cleared via the renal system, with minimal soft tissue activity detected at 48 h after injection, whereas a significant uptake increase (p \ 0.05) was observed in the bone from 24 to 48 h. Interestingly, at the higher dose the complex exhibited significantly lower kidney uptake (p \ 0.05) than at the lower dose within 4 h of injection. This is likely due to the presence of a scavenger receptor, megalin, in the proximal tubes of the kidneys that is responsible for the endocytosis of molecules passing through the kidneys [32] . If this scavenger receptor is exposed to a large amount of the complex shortly after injection, it is likely to become saturated and this would result in the lower kidney uptake of the complex at the higher dose.
Conclusions
The general rule of thumb for identifying a ''stable'' lanthanide contrast agent has been associated with the concept of the highest thermodynamic stability. Indeed this is an important consideration; however, the influence of kinetic inertness should not be underestimated. In the present study we have demonstrated that a cationic lanthanide chelate ( 177 LuL 12 ) possessing unremarkable thermodynamic stability can be tolerated at the typical MRI contrast agent dose. Furthermore, the biodistribution profiles for this series of DOTA-tetraamide complexes bearing peripheral hydroxyl groups are quite similar to those of anionic chelates such as Dotarem, which is accepted as safe for human use. The Ln 3? complexes of the three DOTA-tetraamide ligands were evaluated with respect to thermodynamic and kinetic properties and the data acquired for complexes of L 4 and L 8 were similar to those obtained for other DOTA-tetraamide complexes. The data acquired for L 12 are less easily understood; nonetheless, the in vivo results are significant and indicate that sufficient peripheral hydroxyl functionalization can be used to mask and control undesirable features of the chelate. Finally, the utility of DOTA-tetraamide ligands is not limited to PARACEST applications. These ligands can also be modified to include bifunctional linkers enabling covalent attachment to targeting vectors. In this manner the desirable kinetic properties of these unique ligands can further extend their applications to other modalities such as nuclear medicine.
